In the JAMA Insights article titled “Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,” published July 20, 2021, the dosing of inclisiran required clarification. The fourth sentence of the “Inclisiran” section that stated that inclisiran was dosed as “1 to 3 injections administered over a 3-month period, followed by dosing once every 6 months” should be replaced with “Clinical trials reveal durable 30% to 60% reductions in LDL-C.10 Inclisiran is dosed by injection at day 1 and day 90, followed by dosing once every 6 months.” This article was corrected online.
Source: JAMA Online First